Dow Jones 30 Stocks SEC Filings — May 14, 2026

14-05-2026

RenovoRx reported record Q1 2026 revenue of $563,000, up 136% QoQ from Q4 2025 and 186% YoY from $197,000 in Q1 2025, representing over 50% of full-year 2025 revenue of $1.1 million, driven by expansion to 16 active commercial cancer centers from 8 at year-end 2025. However, net loss widened to $3.5 million from $2.4 million YoY due to SG&A expenses rising to $2.7 million from $1.6 million amid commercial scaling, despite R&D expenses decreasing to $1.2 million from $1.6 million. The company ended the quarter with $12.4 million in cash after a $10 million private placement, sufficient into H2 2027, and expects TIGeR-PaC trial enrollment completion by June 2026.

• · Targeting 36 active commercial cancer centers by year-end 2026.
• · Full-year 2026 revenue guidance: $3-4 million.
• · Up to 15 TIGeR-PaC trial sites expected to transition to commercial use post-enrollment.
• · RenovoCath sales pipeline quadrupled YoY to 48 centers.
• · ASCO GI Cancers Symposium presentation in January 2026 on pharmacokinetic subset study.
• · Named one of Fast Company’s “World’s Most Innovative Companies of 2026” in Medical Devices.

14-05-2026

For the three months ended March 31, 2026, Versant Media Group reported revenue of $1,687 million, down 1.1% YoY from $1,706 million, with declines in linear distribution (-7.4% to $1,006 million) and advertising (-5.2% to $368 million), partially offset by platforms growth (+9.1% to $192 million) and content licensing (+112% to $121 million). Operating income decreased 11.4% to $442 million from $499 million due to higher SG&A (+14%) and new interest expense, leading to net income of $286 million, down 22.1% from $367 million. However, cash provided by operating activities rose 22.4% to $585 million, supporting $1,196 million in cash at period end amid the separation from Comcast.

• · Long-term debt increased to $2,869 million at March 31, 2026 from $983 million at December 31, 2025, following $1,973 million in borrowings.
• · Repurchased common stock for $100 million under repurchase program and employee plans.
• · Paid dividends of $55 million ($0.375 per common share).
• · Acquisitions of businesses and investments used $145 million in cash.
• · Total equity attributable to Versant $8,034 million at March 31, 2026, after separation-related transactions reducing Net Comcast investment to zero.

14-05-2026

HARBERT FUND ADVISORS, INC. filed a 13F-HR on May 14, 2026, reporting holdings as of March 31, 2026. The filing discloses sole voting authority over 735,768 shares of Identiv Inc. common stock and 92,927 shares of Transact Technologies Inc. common stock. No prior period comparisons, changes, or additional holdings are detailed.

• · Filing accession number: 0000919574-26-003023
• · SEC file number: 028-16265
• · Company address: 2100 Third Avenue North, Suite 600, Birmingham, AL 35203

14-05-2026

HighPoint Advisor Group LLC filed its 13F-HR on May 14, 2026, reporting institutional holdings as of March 31, 2026. The portfolio comprises 643 positions with a total value of $2,386,208,832. No prior period data is provided in the filing, resulting in no observable changes.

• · Filer CIK: 0001616034
• · SEC File Number: 028-16828
• · Business Address: 2651 Warrenville Rd Suite 200, Downers Grove, IL 60515

14-05-2026

On May 12, 2026, AIxCrypto Holdings, Inc. (AIXC) entered into a Note Purchase Agreement with CABG Acquisition Corp. to sell its Note Package related to Marizyme, Inc., including a secured promissory note with $4,771,142 principal plus 18% accrued interest and a $1,750,000 Co-Development Note tied to DuraGraft product success, in exchange for $100,000 cash (a significant discount to face value), 10% royalties on net revenues exceeding $20,000,000, and a 4.99% membership interest in the Buyer. The Buyer commits to commercializing Marizyme's assets, with closing subject to mutual agreement within 90 days or terminable by either party. The transaction provides immediate liquidity but relinquishes direct creditor rights and potential full upside from Marizyme.

• · Note amendments dated September 15, 2025 and October 2, 2025; Co-Development Note dated April 11, 2024, amended August 6, 2024.
• · Security interest in substantially all Marizyme assets; all UCC filings transferred.
• · Customary preemptive rights and registration rights for the 4.99% membership interest.
• · Agreement terminable if closing not within 90 days of May 12, 2026, unless material breach.

14-05-2026

14-05-2026

14-05-2026

14-05-2026

14-05-2026

14-05-2026

Archer Aviation Inc. filed a prospectus supplement on May 14, 2026, for the resale of 3,266,870 shares of Class A common stock issued to selling stockholders pursuant to stock purchase agreements dated on or about May 13, 2026. The company also plans to issue up to an aggregate $8 million of Class A common stock shares to vendors around May 19, 2026, in satisfaction of payments for services rendered and goods purchased. Both offerings are under the existing Registration Statement on Form S-3 (No. 333-284812).

• · Prospectus supplement filed pursuant to Rule 424(b) under the Securities Act.
• · Registration Statement on Form S-3 (No. 333-284812) originally filed February 11, 2025.
• · Legal opinions filed as Exhibits 5.1 (Resale Shares) and 5.2 (Vendor Shares).

14-05-2026

Verizon Communications Inc. closed the sale of $2,000,000,000 aggregate principal amount of its 6.050% Fixed-to-Fixed Rate Junior Subordinated Notes due 2058 and $2,000,000,000 aggregate principal amount of its 6.200% Fixed-to-Fixed Rate Junior Subordinated Notes due 2056 on May 14, 2026. The notes were sold to a group of underwriters led by BNP Paribas Securities Corp., Goldman Sachs & Co. LLC, and others pursuant to an effective shelf registration statement on Form S-3 (Reg. No. 333-289928) effective August 29, 2025. This filing incorporates the forms of the global notes as exhibits to the registration statement.

• · Notes sold pursuant to purchase agreement with listed underwriters acting as representatives.
• · Registration Statement on Form S-3 (Reg. No. 333-289928) became effective upon filing on August 29, 2025.
• · Exhibits 4.1 and 4.2: Forms of Global Notes for the respective notes.

14-05-2026

Vernal Capital Acquisition Corp., a blank check company, consummated its IPO on May 7, 2026, selling 10,000,000 public units at $10.00 each for $100,000,000 gross proceeds and 251,250 private units to sponsors for $2,512,500, depositing $100,500,000 into a trust account. The balance sheet as of May 7, 2026, shows total assets of $101,518,073, with $793,727 in shareholders' equity. However, the auditor's report raises substantial doubt about the company's ability to continue as a going concern if it fails to complete an initial business combination within 15 months (or up to 21 months if extended).

• · Cash outside trust: $943,073; cash held in trust for over-allotment: $75,000.
• · Over-allotment option liability: $135,280.
• · Founder shares retroactively restated: 2,875,000 issued to sponsors for $25,000, including up to 375,000 subject to forfeiture.
• · Business combination must have fair market value of at least 80% of trust assets (excluding deferred underwriting commissions and taxes).
• · IPO registration statement effective May 5, 2026; must complete business combination within 15 months from May 7, 2026 (or up to 21 months if extended).

14-05-2026

Enovix reported Q1 FY2026 revenue of $7,600 up 49% YoY from $5,098, with gross profit surging 495% to $1,552 from $261 driven by improved margins. However, operating expenses rose 6% to $45,447, leading to a wider net loss of $38,260 (up 63% YoY from $23,510), and stockholders' equity declined 11% to $240,672. Cash and equivalents fell 16% to $88,751 from $106,014 at year-end amid $33,072 used in operations.

• · Net cash provided by investing activities: $18,330 (vs. $64,371 used YoY)
• · Interest expense: $7,008 (up from $1,716 YoY)
• · Stock-based compensation expense: $11,765 (in cash flow adjustments)
• · Weighted average shares outstanding: 217,371,926 (up from 203,328,890 YoY)
• · Cash paid for interest: $8,671 (up significantly from $128 YoY)

14-05-2026

Barfresh Food Group Inc. reported Q1 2026 revenue of $5,632,000, a 92% YoY increase from $2,930,000, driven by higher sales volumes, with gross profit rising 15% to $1,033,000 and total operating expenses declining 10% to $1,469,000, narrowing the net loss to $661,000 from $761,000. However, interest expense surged to $225,000 from $23,000 due to new financing, and net cash used in operating activities more than quadrupled to $2,382,000 from $506,000 amid working capital changes. Manufacturing concentration shifted, with owned production at 53% (up from 0%), but reliance on Manufacturer A dropped to 18% from 52%.

• · Property and equipment, net increased to $8,361,000 as of March 31, 2026 from $8,297,000 at December 31, 2025.
• · Inventory, net rose to $1,805,000 as of March 31, 2026 from $1,665,000 at December 31, 2025, driven by higher raw materials.
• · Net cash provided by financing activities was $4,527,000 in Q1 2026, including $7,374,000 from convertible debt issuance and $3,791,000 borrowings offset by repayments.
• · Purchase of property and equipment increased to $646,000 in Q1 2026 from $28,000 in Q1 2025.
• · Cash paid for interest was $185,000 in Q1 2026 vs. $19,000 in Q1 2025.

14-05-2026

14-05-2026

14-05-2026

On May 14, 2026, Strategic Storage Trust VI, Inc. issued a press release announcing it was ranked the top lifecycle REIT over a three-year period according to Robert A. Stanger & Co. The press release is attached as Exhibit 99.1 and furnished under Item 7.01 for Regulation FD purposes.

14-05-2026

14-05-2026

Kennedy-Wilson, Inc., a wholly-owned subsidiary of Kennedy-Wilson Holdings, Inc., announced the pricing of a $1.8 billion private offering of senior notes, comprising $1.1 billion 7.000% notes due 2031 and $700 million 7.250% notes due 2033, offered under Rule 144A and Regulation S. Proceeds, if the pending merger closes, will redeem existing lower-rate notes due 2029, 2030, and 2031, and repay credit facility debt, with funds held in escrow until merger consummation and subject to special mandatory redemption at 100% if the merger fails by November 16, 2026. The notes carry higher interest rates (7.000%-7.250%) compared to existing notes (4.750%-5.000%), reflecting elevated borrowing costs amid the merger process.

• · Merger Agreement dated February 16, 2026, amended March 25, 2026
• · Special mandatory redemption if Merger not consummated by November 16, 2026, at 100% of initial issue price plus accrued interest
• · Fairfax committed to fund any escrow shortfall for redemption
• · Notes offered only to qualified institutional buyers and non-U.S. persons under Rule 144A and Regulation S

14-05-2026

As of April 30, 2026, Invesco Real Estate Income Trust Inc. reported a total net asset value (NAV) of $640,215 thousand, with NAV per share ranging from $26.0402 for Class T shares to $28.2395 for Class E shares and Operating Partnership units. The portfolio consists of 70 real estate properties totaling approximately 11.4 million square feet across 32 U.S. markets with a weighted average occupancy of 94%, direct real estate investments representing 79% of gross assets, real estate debt at 17%, and a leverage ratio of 30%. Quarter-to-date through April 30, 2026, the company raised $9.8 million in gross proceeds from offerings, including the DST Program and distribution reinvestment plan, and fulfilled all $6.3 million in common stock repurchase requests.

• · Real estate portfolio includes property types such as Healthcare (discount rate 7.2%, exit cap rate 5.8%), Office (9.7%, 7.3%), Industrial (7.8%, 5.8%), Self-Storage (7.6%, 5.8%), Multifamily (7.5%, 5.5%), Student Housing (8.0%, 5.8%), Retail (8.4%, 7.3%), and Manufactured Housing Community (10.1%, 5.6%).
• · NAV calculation excludes discounts for illiquidity or exit costs and is not derived from listed fund market prices.

14-05-2026

LanzaTech reported Q1 2026 revenue of $12.0 million, up 26% YoY from $9.5 million, primarily driven by $6.4 million in engineering services (vs $1.8 million prior year), though partially offset by declines in JDA revenue ($0 vs $1.1 million), licensing ($0.6 million vs $1.1 million), contract research ($1.0 million vs $1.4 million), and flat CarbonSmart sales ($4.1 million vs $4.2 million). Net loss narrowed to $14.7 million from $19.2 million and Adjusted EBITDA loss improved to $7.9 million from $30.5 million, supported by a 59% drop in operating expenses to $13.5 million from $33.0 million; cost of revenue rose slightly to $8.3 million from $7.5 million. The company raised $30 million in gross proceeds from private placements ($20 million in January and $10 million in May, with option for additional $20 million), boosting cash to $23.8 million and alleviating going concern doubts, alongside project milestones like India ethanol plant contract and Japan MSW performance.

• · LanzaJet Series A at $650M pre-money valuation; LanzaTech ownership reduced to ~46%.
• · Japan MSW-Ethanol plant achieved ethanol yields exceeding guaranteed performance from unsorted MSW syngas.
• · Going concern substantial doubt alleviated post-capital raises and cost optimizations.

14-05-2026

14-05-2026

14-05-2026

KLX Energy Services Holdings, Inc. (KLXE) filed an S-3 shelf registration statement on May 14, 2026, incorporating recent financial reports and enabling future issuance of securities for general corporate purposes such as debt repayment, acquisitions, capital expenditures, and working capital. The company, a provider of oilfield services including coiled tubing, hydraulic fracturing rentals, and related products, has 110 million authorized shares of common stock ($0.01 par) and 11 million preferred shares, with 19,911,759 common shares outstanding as of April 30, 2026. No specific financial performance metrics or period comparisons are disclosed in the filing.

• · Incorporated in Delaware on June 28, 2018; spin-off from KLX Inc. completed September 14, 2018.
• · Principal executive offices: 3040 Post Oak Boulevard, 15th Floor, Houston, Texas 77056; phone (832) 844-1015.
• · Website: www.klx.com (information not part of prospectus).
• · Board structure includes classified board with three classes, serving three-year terms; anti-takeover provisions in Certificate and Bylaws.

14-05-2026

Corvus Pharmaceuticals presented final data from its randomized, placebo-controlled Phase 1 trial of soquelitinib in 72 patients with moderate-to-severe atopic dermatitis, demonstrating a favorable safety profile with adverse events in 41.7% of both soquelitinib and placebo arms (all Grade 1-2, no serious events or dose modifications). Efficacy showed dose-dependent trends, with 50% of cohort 3 and 75% of cohort 4 (200 mg BID) achieving EASI 75, durable remissions without rebound during post-treatment follow-up, and comparable results in prior systemic therapy patients. Biomarker analyses confirmed mechanism of action, including Th2/Th17 reduction, Treg increase, and JAK-STAT inhibition.

• · Trial included patients who failed prior topical/systemic therapy; 28-day dosing in cohorts 1-3 (100 mg BID, 200 mg QD, 200 mg BID), 56-day in cohort 4 (200 mg BID).
• · No significant lab abnormalities, dose modifications, interruptions, severe, or serious adverse events.
• · Disease control persisted through 30-90 day post-treatment follow-up with no rescue medications needed, unlike approved therapies.
• · Biomarkers: dose-dependent Th2 reduction, persistent Treg increase, SOCS3 upregulation, JAK1/STAT6 reduction.

14-05-2026

Aveanna Healthcare Holdings reported Q1 2026 revenue of $647.9 million, up 15.9% YoY from $559.2 million, driven by growth across all segments including PDS (+$75.7 million), HHH (+$9.9 million), and MS (+$3.2 million); net income rose to $41.7 million from $5.2 million, and Adjusted EBITDA increased 25.2% to $84.4 million. However, gross margin percentage declined to 31.7% from 32.8%, and free cash flow was negative at $(3.8) million despite $4.3 million in operating cash flow. The company raised FY2026 guidance to revenue of $2.56-$2.58 billion (from $2.54-$2.56 billion) and Adjusted EBITDA of $328-$332 million (from $318-$322 million), excluding the pending Family First Homecare acquisition.

• · PDS segment revenue increased $75.7 million YoY; HHH +$9.9 million; MS +$3.2 million.
• · Q1 2026 net cash provided by operating activities $4.3 million; free cash flow $(3.8) million.
• · Interest rate hedges: $520.0 million swaps, $880.0 million caps at SOFR 2.96%.
• · Pending acquisition expected to reduce liquidity upon closing.
• · Conference call held May 14, 2026 at 10:00 a.m. ET.

14-05-2026

Cabaletta Bio, Inc. reported a widened net loss of $43,515 thousand for the three months ended March 31, 2026, up 21% YoY from $35,943 thousand, primarily due to research and development expenses rising 29% YoY to $37,353 thousand while general and administrative expenses declined 15% to $6,943 thousand. Cash and cash equivalents increased 41% QoQ to $116,635 thousand from $82,982 thousand at December 31, 2025, supported by $50,960 thousand from investment maturities and $29,538 thousand in net proceeds from equity issuances, though operating cash use intensified to $42,561 thousand. Total assets fell to $148,146 thousand from $165,083 thousand, with stockholders' equity decreasing to $103,305 thousand from $112,051 thousand amid the larger accumulated deficit of $560,472 thousand.

• · Weighted-average common shares outstanding increased to 112,025,474 in Q1 2026 from 50,743,101 in Q1 2025, improving net loss per share to $(0.39) from $(0.71).
• · Proceeds from ATM offering: $22,568 thousand; from warrant exercises: $6,938 thousand in Q1 2026.
• · Short-term investments fully matured at $50,617 thousand as of December 31, 2025, contributing to cash increase.

14-05-2026

Yorkville International Capital Corp., a Cayman Islands blank check company focused on acquiring established businesses in emerging markets with emphasis on Latin America and Venezuela, filed an S-1 registration statement on May 14, 2026, for an initial public offering of 20,000,000 units priced at $10.00 each, targeting gross proceeds of $200,000,000. Each unit consists of one Class A ordinary share and one-third of one redeemable warrant, with whole warrants exercisable at $11.50 per share starting 30 days after the offering completion. The sponsor, Yorkville International Capital Sponsor LLC, and certain insiders hold founder shares, private placement warrants, and convertible securities.

• · Principal executive offices: 1012 Springfield Avenue, Mountainside, New Jersey 07092.
• · Incorporated in Cayman Islands; no selected business combination target.
• · Insiders and sponsor may receive reimbursements for expenses, working capital loans, finder’s fees, and monthly office/administrative services.
• · Offering costs, shareholder redemptions, and deferred underwriting commissions vary by over-allotment option exercise and redemption scenarios (e.g., 25%, 50%, 75%, 100% redemption levels).

14-05-2026

Migdal Insurance & Financial Holdings Ltd. filed its Form 13F-HR on May 14, 2026, disclosing U.S. equity holdings as of March 31, 2026, managed by its wholly-owned subsidiaries including Migdal Insurance Company Ltd., Migdal Makefet Pension and Provident Fund Ltd., Migdal Mutual Funds Ltd., and Migdal Investment Portfolio Management (1998) Ltd. Key positions include Alphabet Inc. CAP STK CL C valued at $440,308,016 (1,535,050 shares), Invesco Exchange Traded Fund Trust II S&P500 EQL WGT at $364,648,000 (1,900,000 shares), and Amazon.com Inc. COM at $297,436,635 (1,428,130 shares). The filing notes independent management by each entity and includes only U.S.-purchased dual-listed securities per SEC guidance.

• · Beneficial ownership in a portion of securities held for members of the public through provident funds, mutual funds, pension funds, and insurance policies.
• · Each Migdal Entity operates under independent management with independent voting and investment decisions.
• · Filing disclaims formation of any 'group' under Section 13(d) and beneficial ownership beyond actual pecuniary interest.
• · Dual-listed securities (U.S. and Tel Aviv Stock Exchange) included only if purchased in the U.S., per informal SEC guidance.

14-05-2026

Western New England Bancorp, Inc. (WNEB) presented at its 2026 Annual Shareholders’ Meeting, highlighting 2025 quarterly financials with net income improving to $5,209 thousand in 4Q2025 (EPS $0.26, ROA 0.75%) from $2,303 thousand in 1Q2025 (EPS $0.11, ROA 0.35%), and Q1 2026 results showing EPS of $0.24 (up YoY from $0.11 but down QoQ from $0.26) with ROA at 0.71% (up YoY but down QoQ from 0.75%). Balance sheet grew with total loans at $2.3 billion as of March 31, 2026 (up from $2.1 billion YoY) and deposits at approximately $2.4 billion, while NIM improved to 2.97% tax-equivalent basis in Q1 2026 (up QoQ from 2.91%). However, ROE declined QoQ to 7.77% from 8.40%, and certain quarters showed provisions for credit losses.

• · Shareholder proposals include election of four directors (Laura J. Benoit, Donna J. Damon, Lisa G. McMahon, Steven G. Richter) for three-year terms, advisory vote on executive compensation, and ratification of Wolf & Company, P.C. as independent auditor for FY 2026.
• · Strong asset quality in 2025: Allowance for Credit Losses at 0.93% of total loans, coverage of nonaccrual loans at 393%, nonaccrual loans 0.32% of total loans.
• · Loan-to-asset ratio reached 80% in 2025, up from 73% historically; borrowings-to-total assets at 4%.

14-05-2026

Mizuho Bank, Ltd. filed a 13F-HR disclosing $369,481,064 in U.S. equity holdings as of March 31, 2026. The portfolio consists of four positions: SPDR S&P 500 ETF Trust ($102,753,720, 158,000 shares), Select Sector SPDR Energy ($200,932,800, 3,280,000 shares), Invesco DB Multi-Sector Comm Agriculture Fund ($35,516,000, 1,300,000 shares), and CME Group Inc. ($30,278,544, 102,518 shares). No share changes were reported for these holdings.

• · Filing period end date: March 31, 2026
• · Filed on: May 14, 2026
• · Business address: 1-5-5, Otemachi, Chiyoda-ku, Tokyo 100-8176, Japan

14-05-2026

Invivyd reported Q1 2026 PEMGARDA net product revenue of $13.7 million, up 22% YoY from $11.3 million, while maintaining a strong cash position of $184.2 million plus ~$20 million from April ATM proceeds. However, R&D expenses surged to $30.7 million from $10.6 million and SG&A to $25.1 million from $16.8 million due to DECLARATION trial costs, resulting in a net loss of $41.4 million versus $16.3 million in Q1 2025. Clinical progress includes positive in vitro data for PEMGARDA and VYD2311 against BA.3.2.2 variant and IDMC recommendations easing DECLARATION trial monitoring.

• · DECLARATION trial full initial enrollment achieved in March 2026; upsized by ~500 subjects, top-line data now Q3 2026.
• · IDMC recommended reducing post-dose monitoring from 2 hours to 30 minutes; pregnant/breastfeeding women eligible, no contraception required for women of childbearing age.
• · Positive in vitro neutralization of PEMGARDA and VYD2311 against SARS-CoV-2 BA.3.2.2 (Cicada) variant.
• · Pipeline: VMS063 measles mAb IND readiness late 2026; VBY329 pediatric RSV IND 2H 2026 targeting $3-4B market by 2030.

14-05-2026

DC Investments Management, LLC filed its quarterly 13F-HR on May 14, 2026, reporting total equity holdings valued at $261,233,675 as of March 31, 2026, across 76 positions. The portfolio is heavily weighted toward the Vanguard FTSE All-World ex-US ETF ($122,427,309), followed by the SPDR S&P MidCap 400 ETF ($18,917,879) and Piedmont Realty Trust Inc. ($4,892,377). No option positions or voting authority deviations were reported.

• · Filing period end date: March 31, 2026
• · All positions held with sole discretionary voting authority (SH DFND 1)
• · No put or call options reported (all 0)

14-05-2026

Intelligent Bio Solutions Inc. reported fiscal Q3 2026 revenue of $1,060,802, up 46% YoY from $728,867, driven by cartridge sales growth of 59% to $703,538 (66% of revenue) and other sales up 80% to $217,857, though reader sales declined 16% to $139,407. Nine-month revenue reached $3,069,373, up 39% YoY from $2,208,648, with gross margins expanding to 50.5% in Q3 (from 46.8%) and 49.3% for the nine months (up 800 basis points). Despite revenue gains, Q3 net loss widened to $2,869,640 from $2,550,674, reflecting higher operating expenses.

• · Cash and cash equivalents increased to $6,862,204 at March 31, 2026 from $740,371 at December 31, 2025.
• · Total assets $14,862,792 at March 31, 2026, up from $8,249,786 at June 30, 2025.
• · Q3 operating loss $2,947,101, wider than $2,560,329 YoY.
• · Nine-month operating expenses $10,584,443, up from $8,917,114 YoY.

14-05-2026

SpringBig Holdings, Inc. reported Q1 2026 net revenues of $5,444 thousand, down 1.3% YoY from $5,516 thousand, while gross profit declined 16.8% to $3,586 thousand due to higher cost of revenues rising 54.1% to $1,858 thousand. Operating expenses fell 21.4% YoY to $3,725 thousand, leading to a narrower net loss of $494 thousand versus $751 thousand in Q1 2025. Cash and total assets decreased QoQ to $1,271 thousand and $4,280 thousand respectively, with net cash used in operating activities worsening to $229 thousand from $86 thousand YoY.

• · Allowance for credit losses increased to $381 thousand from $300 thousand QoQ.
• · Stock-based compensation expense decreased to $71 thousand from $163 thousand YoY.
• · Long-term debt current portion $9,756 thousand at Mar 31 2026 (previously non-current).

14-05-2026

BGSF, Inc.'s amended 10-Q for the thirteen weeks ended March 29, 2026 (Q1 2026) shows a stable ending allowance for credit losses at $1,156 thousand, up 15.6% YoY from $1,000 thousand, with provision expense down significantly to $96 thousand from $198 thousand. However, amounts written off increased to $130 thousand from $112 thousand, total receivables declined to $1,313 thousand from $1,458 thousand QoQ, and computer software amortization expense dropped to $133 thousand from $299 thousand YoY. Weighted-average common shares outstanding decreased slightly to 10,684 thousand from 10,954 thousand YoY.

• · CARES Act receivable reduced to $0 from $280 thousand QoQ.
• · Weighted average remaining contractual life of options decreased to 5.0 years from 5.2 years.
• · Total intrinsic value of options outstanding increased to $124 thousand from $52 thousand.

14-05-2026

MSD Investment Corp.'s Q1 2026 10-Q shows total assets increasing 6.4% QoQ to $7,012,012, driven by non-controlled/non-affiliated investments rising 6.8% to $6,824,822, while total investment income grew 23.5% YoY to $164,562 and net investment income rose 23.9% to $80,819. However, net unrealized depreciation of $31,814 contributed to a slight 2.3% YoY decline in net increase from operations to $60,852 versus $62,271, leading to total net assets dipping 0.1% QoQ to $3,274,323 and NAV per share falling 0.6% to $23.58 from $23.71.

• · Distributions declared per common share: $0.57 (down from $0.65 YoY)
• · Earnings per share: $0.44 (down from $0.62 YoY)
• · Total expenses: $83,743 (up 23.1% YoY from $68,050)
• · Net cash used in operating activities: $(340,099)
• · Revolving credit facility: $580,000 (up from $160,000 QoQ)

14-05-2026

For Q1 2026, BitGo Holdings reported revenue of $3,773,573, more than doubling 113% YoY from $1,774,664, driven by higher digital asset sales. However, total expenses rose to $3,793,477 (114% YoY), resulting in an operating loss of $19,904 versus a $2,349 profit in Q1 2025, and net loss widened to $60,673 (136% larger YoY) due to unrealized losses on digital assets. Total assets grew 30% QoQ to $5,892,241 as of March 31, 2026, bolstered by $174,285 net IPO proceeds and increased stablecoin holder deposits.

• · Cash and cash equivalents segregated for stablecoin holders increased to $4,392,828 from $3,313,527 QoQ.
• · Net cash provided by financing activities was $1,200,438 in Q1 2026, primarily from IPO and stablecoin deposits.
• · Weighted-average shares for Class A and B common stock: 98,409 thousand in Q1 2026.

14-05-2026

Karman Holdings Inc. reported Q1 2026 revenue of $151,210 up 51% YoY from $100,124, gross profit of $63,865 up 62% YoY, and net income of $7,794 versus a $4,798 loss in Q1 2025. The company acquired Seemann Composites and Materials Sciences for $210,150 cash plus $15,205 in stock, driving total assets to $1,417,738 from $1,104,096 QoQ and boosting goodwill and intangibles; however, this led to a $217,525 investing cash outflow and long-term notes payable surging to $752,180 from $495,312. Operating cash flow improved to $209 from $(13,584) YoY, with cash equivalents at $73,798.

• · Interest expense net $12,646 in Q1 2026 vs $11,373 in Q1 2025.
• · Contract assets increased to $169,370 from $156,298 QoQ.
• · Depreciation and amortization $13,776 operating + $16,633 cash flow adj in Q1 2026.

14-05-2026

StubHub Holdings reported Q1 2026 revenue of $446,045 thousand, up 12.2% YoY from $397,607 thousand, swinging to net income of $48,045 thousand from a $22,183 thousand loss, driven by lower interest expense and foreign currency gains. However, income from operations declined 3.7% to $25,829 thousand amid a 49.1% surge in general and administrative expenses to $105,645 thousand. Cash flow from operations more than doubled to $298,416 thousand YoY, boosting cash and equivalents to $1,526,237 thousand from $1,241,587 thousand at year-end.

• · Redeemable preferred stock decreased to $454,350 thousand (490,000 shares) from $758,027 thousand (794,893 shares) due to conversions to Class A common stock.
• · Long-term debt obligations slightly decreased to $1,496,227 thousand from $1,506,957 thousand.
• · Stock-based compensation expense increased to $37,729 thousand from $5,605 thousand YoY.
• · Payments due to buyers and sellers rose to $1,111,677 thousand from $845,892 thousand QoQ.

14-05-2026

Cheetah Net Supply Chain Service Inc. reported Q1 2026 revenue of $92,700 from logistics and warehousing, down 80.7% YoY to $479,799, driven by Edward segment decline of 36.5% to $39,700 amid planned sale and TWEW drop of 87.3% to $53,000 due to tariff policy changes. Operating loss narrowed 20.4% to $764,319 and net loss from continuing operations improved 18.3% to $616,265, aided by 23.0% reduction in G&A expenses to $770,004 through cost discipline. The company completed private placement and ATM financings, entered a Share Transfer Agreement for a Hong Kong industrial equipment trader acquisition targeting May close, but noted $2.5M net cash used in operations and going concern doubts.

• · Net cash used in operating activities (continuing operations): $2,457,939 for Q1 2026.
• · Cash and cash equivalents increased to $713,948 from $233,217 at Dec 31, 2025.
• · Going concern doubts raised due to ongoing operating losses and negative cash flow.
• · No income or expenses from discontinued parallel-import vehicle business in Q1 2026.

14-05-2026

VIVIC CORP reported no revenue for the three and nine months ended March 31, 2026, compared to zero revenue in the three months and $44,243 in the nine months of the prior year, resulting in a net loss of $51,815 for the quarter (vs $950,807 prior year, a 95.5% reduction in loss magnitude) and $552,765 for the nine months (vs $2,498,000 prior year, 77.9% smaller loss). Total assets declined 29.1% to $2,738,062 from $3,859,558 at June 30, 2025, driven by a sharp drop in cash to $13,985 from $41,903, while total liabilities decreased 36.1% to $1,311,393 and stockholders' equity fell to $1,426,669 from $1,807,191. Net cash used in operating activities improved to $304,578 from $511,134 over nine months, supported by financing inflows.

• · Share-based compensation for three months ended March 31, 2026: $8,500 (vs $829,292 prior year).
• · SBA loan payable unchanged at $87,500.
• · Property and equipment, net: $0 as of March 31, 2026 (vs $302 at June 30, 2025).
• · Inventory: $0 as of March 31, 2026 (vs $4,249 at June 30, 2025).

14-05-2026

Net sales rose 8.4% YoY to $380,414 driven by 18.5% growth in wholesale to $183,595, while direct-to-consumer sales were essentially flat at $196,819; category growth included 11.4% in Coolers & Equipment and 5.5% in Drinkware. However, operating income fell 42.6% to $12,438 due to a 9.8% increase in SG&A expenses to $197,773, leading to net income declining 40.7% to $9,851. Cash and total assets decreased QoQ to $127,791 and $1,218,618, respectively, with net cash used in operations improving to $(32,649) from $(80,296) YoY.

• · Gross profit increased to $210,211 from $201,722 YoY.
• · Net cash used in operating activities improved to $(32,649) from $(80,296) YoY.
• · International net sales grew 9.4% YoY to $87,328.

14-05-2026

On May 13, 2026, Advanced Energy Industries, Inc. announced the pricing of an offering of $1 billion aggregate principal amount of its 0% Convertible Senior Notes due 2031 in a private transaction exempt from the registration requirements of the Securities Act of 1933. The press release detailing the announcement is attached as Exhibit 99.1. No other financial metrics or period comparisons were provided in the filing.

• · Filing signed by Paul Oldham on May 13, 2026
• · Notes issued in a private transaction exempt from Securities Act registration

14-05-2026

Reliance Global Group, Inc. filed Articles of Amendment to its Articles of Incorporation, implementing a 1-for-40 reverse stock split effective upon filing with the Florida Division of Corporations, reducing authorized Common Stock from 2,000,000,000 to 50,000,000 shares (97.5% reduction) and setting total authorized shares at 800,000,000 including 750,000,000 Preferred Stock shares. The amendment was adopted by the Board of Directors via unanimous written consent on May 7, 2026, without shareholder approval, with Nasdaq trading effective expected on May 18, 2026. No fractional shares will be issued; holders receive one whole share rounded up.

• · Articles adopted pursuant to Sections 607.1006, 607.10025, and 607.10025(7) of the Florida Business Corporation Act.
• · Signed on May 12, 2026.
• · Transfer agent authorized to round up fractional shares to one whole share.

14-05-2026

First International Bank of Israel Ltd., a subsidiary of F.I.B.I. Holdings Ltd., filed its 13F-HR on May 14, 2026, disclosing 59 U.S.-listed equity holdings as of March 31, 2026, primarily consisting of ETFs and select large-cap stocks. Significant positions include $38.2M in FIRST TR EXCHNG TRADED FD VI FT VEST US EQT (CUSIP 33740U679) and $28.9M in FIRST TR EXCHNG TRADED FD VI FT VEST US (CUSIP 33740F631), alongside stocks like Amazon.com Inc. ($5.6M) and Apple Inc. ($2.3M). The Bank manages these directly, through subsidiaries, or via HaBeinleumi Unique Portfolio Management Ltd. for clients, disclaiming any control group with its parent.

• · Securities reported are beneficially owned by the Bank, subsidiaries, or purchased by Unique on behalf of clients with investment discretion.
• · Filer and parent F.I.B.I. Holdings Ltd. operate under independent management with separate voting and investment decisions.
• · Includes only dual-listed securities on U.S. and Tel Aviv exchanges that were purchased in the U.S., per SEC guidance.
• · Business address: 42 Rothschild Blvd, Tel Aviv, L3 6688310, Israel